After a Phase 3 NSCLC failure traced to a manufacturing scale error, efti's survival depends on whether two smaller bets — HNSCC and STS — can carry the program to approval

Immutep is a clinical-stage biopharmaceutical company developing eftilagimod alfa, a targeted immunotherapy for three cancer types—non-small-cell lung cancer, head and neck cancer, and soft tissue sarcoma—none of which have yet approved this drug.

Immutep's LAG-3 agonist eftilagimod alfa suffered a Phase 3 futility call in first-line NSCLC, with root cause analysis blaming N-glycan differences at 2,000 L versus 200 L manufacturing scale. The thesis now rests on two earlier-stage indications: FDA-endorsed registrational paths in PD-L1 CPS-negative HNSCC and neoadjuvant soft tissue sarcoma, both pre-registration and unproven at confirmatory scale. The manufacturing attribution remains a hypothesis, and single-arm or small-cohort registrational designs carry inherent approvability risk if confirmatory data disappoint.